Navigation Links
Dr. Andrew Scharenberg, M.D., to Serve as Chief Scientific Officer for Cellectis therapeutics
Date:7/11/2011

PARIS, July 11, 2011 /PRNewswire/ -- Cellectis therapeutics, a subsidiary of Cellectis (Alternext: ALCLS) specializing in the development of therapeutic applications in genome engineering, today announced the appointment of Dr. Andrew M. Scharenberg as Chief Scientific Officer.

Dr. Scharenberg is an attending physician in Immunology at Seattle Children's Hospital, and Professor of Pediatrics and Immunology at the University of Washington. His academic laboratory is based at Seattle Children's Research Institute, and is world renowned for its work on the development of genome engineering technologies for innovative therapeutic applications.

Dr. Scharenberg is a principal investigator and codirector of the Northwest Genome Engineering Consortium (NGEC), which is focused on new approaches for treating genetic diseases. In addition, he is a cofounder and member of the Board of Director's of Pregenen Inc., a biotechnology spin-off from the NGEC, and a strategic partner of Cellectis focused on the commercial development of novel genome engineering technologies.

"We are thrilled that Andrew Scharenberg has accepted the post of Chief Scientific Officer of our therapeutic subsidiary," stated Chief Scientific Officer of the Cellectis group Frederic Paques. "His experience and energy will push our research teams to achieve their full potential."

About Cellectis therapeutics

Founded in 2008, Cellectis therapeutics is dedicated to the development of innovative therapeutic approaches that use meganucleases to treat genetic diseases, cancers, and persistent viral infections. Its prospective treatment targets the DNA sequence that causes disease, which may be innate (genetic disease) or acquired (viral infection, cancer). Cellectis therapeutics' aim is to fulfill unmet medical needs, giving patients new hope.

About Cellectis

Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including agriculture, bioresearch and human therapeutics. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris.

For further information about Cellectis, visit our website at: www.cellectis.com

Follow Cellectis on twitter : http://twitter.com/cellectis

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.


'/>"/>
SOURCE Cellectis
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Genesis Biopharma Appoints William H. Andrews Ph.D. to Board of Directors
2. Andrew P. Mandell - Mr. Diabetes(R) to Sit On ProtoKinetix Advisory Board
3. Jonathan Moreno and Andrew Light Speak About Biotechnology and Global Warming at the National Press Club
4. BioNeutral Groups CEO, Stephen Browand and Chief Scientist, Dr. Andrew Kielbania to Appear on WVOX 1460 AM In Focus Radio Show Hosted by Dr. Dan Miller
5. Veridiam Appoints Andrew Gale as Chief Executive Officer
6. Andrew Chisholm Appointed Vice President, Sales and Corporate Accounts at Accumetrics
7. Algeta Appoints Andrew Kay as President and Chief Executive Officer
8. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
9. Saladax Biomedical, Inc. Announces Appointment of Gregory C. Critchfield, M.D., M.S. as Chairman of the Companys Board of Directors
10. Patrick Hwu, M.D., and Mario Sznol, M.D., Join Genesis Biopharmas Scientific and Medical Advisory Board
11. BioNeutral Elects Stephen Holt, M.D., Ph.D as Vice Chairman and Independent Director of the Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017  SkylineDx ... London (ICR) and University of Leeds ... to risk-stratify patients with multiple myeloma (MM), in a multi-centric ... The University of Leeds is the ... UK, and ICR will perform the testing services to include ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new study published ... frozen and fresh in vitro fertilization (IVF) transfer cycles. The multi-center ... success. , After comparing the results from the fresh and frozen transfer cohorts, ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... ... 2017 , ... For the second time in three years, ... Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October 10th, ... mission is to change the trajectory of STEM education in America by dramatically ...
Breaking Biology Technology:
(Date:4/18/2017)... SUNNYVALE, Calif. , April 18, 2017  Socionext Inc., a ... prototype of a media edge server, the M820, which features the ... face recognition software provided by Tera Probe, Inc., will be showcased ... and at the NAB show at the Las Vegas ... ...
(Date:4/13/2017)... Calif. , April 13, 2017 UBM,s ... York will feature emerging and evolving technology ... Both Innovation Summits will run alongside the expo portion ... speaker sessions, panels and demonstrations focused on trending topics ... largest advanced design and manufacturing event will take place ...
(Date:4/11/2017)... GARDENS, Fla. , April 11, 2017 /PRNewswire/ ... management and secure authentication solutions, today announced that ... by Intelligence Advanced Research Projects Activity (IARPA) to ... IARPA,s Thor program. "Innovation has been ... and IARPA,s Thor program will allow us to ...
Breaking Biology News(10 mins):